

PREVENTION OF VENOUS THROMBOEMBOLISM IN GYNECOLOGIC SURGERY

New England Obstetrical and Gynecological Society
May 5, 2010

Daniel L. Clarke-Pearson, MD
Robert A. Ross Professor and Chair
Department of Obstetrics and Gynecology
University of North Carolina




- I have no conflict of interest in the materials being presented.

Learning Objectives

Preventing VTE in Gynecologic Surgery

- After this lecture the gynecologist will
- Explain the importance of venous thromboembolism in gynecologic surgery
- Identify the level of risk in preoperative patients
- Explain the pros and cons of various prophylactic methods
- Based on best evidence, use the appropriate method(s) of VTE prophylaxis in their practice



Scope of the Problem

- 2.5 million cases DVT/yr
- 600,000 episodes of pulmonary embolism (PE)
- PE causes 50,000 deaths/yr
- Over 11,000 postsurgical PE deaths/yr
- Approximately 40% of deaths following Gyn Surgery are due to PE

Fatal Pulmonary Emboli

Two thirds of deaths from pulmonary embolism occur within 30 minutes of the first symptoms

Prevention of Postoperative VTE Issues

- Degree of risk for individual patient
- Outcomes Research: What are our best options?
- Intensity of prophylaxis
- Management Recommendations/Consensus Statements
- Future directions



Pathogenesis of Deep-Vein Thrombosis Virchow's Triad

- Venous stasis
- Hypercoagulability
- Endothelial damage



Variables Associated with DVT in Gynecologic Surgery

- Past history of DVT
- Cancer
- Age >40 >60
- Prior radiation therapy
- Ankle edema
- Varicose veins
- Radical vulvectomy or exenteration
- Prolonged OR time (> 4 hrs)

Clarke-Pearson, *Obstet Gynecol*, 69:146, 1987



Additional DVT Risk Factors

- Pregnancy
- Thrombophilias
- Oral Contraceptives
- Obesity
- Air Travel



Thromboembolism Prophylaxis

- Low-dose heparin
- Low molecular weight heparin
- "Anti-embolism" stockings
- Pneumatic leg compression
- Warfarin
- IVC interruption



LOW-DOSE HEPARIN

Multicenter Trial - Lancet 1975

5,000 Units Subcutaneously On Call to OR and Every 8 Hours

	Controls (2076)	Heparin (2045)	
Fatal PE	16	2	(p<.005)
Death with Associated PE	6	3	(p<.005)




LOW-DOSE HEPARIN In Benign Gynecologic Surgery

Controlled Studies in Gynecology


- Low Dose Heparin 5000 u q 12 hours

	Control	Heparin
Ballard (benign) 1973	29%	3.6%
Adolf (benign) 1978	29%	7%
Taberner (benign) 1978	23%	6%



Does Low Dose Heparin Work for Every Patient?

How about gynecologic
cancer patients?




LOW-DOSE HEPARIN In Gynecologic Oncology Surgery


- 5000 U every 12 hours for 7 day

	DVT (FUT)	(%)
Controls (n=97)	12	(12.4)
Low-Dose Heparin (n=88)	13	(14.8)

Clarke-Pearson. Am J Obstet Gynecol 145:606, 1983



What about a more “intense” Low Dose Heparin Regimen for Cancer Patients?




LOW-DOSE HEPARIN (Intense Regimens) Gynecologic Oncology Surgery

PROSPECTIVE STUDY GYNECOLOGY ONCOLOGY

	% DVT
Control (103)	18
8 hour regimen (104)	9.6
“Load” regimen (97)	6


(p = .02)

Clarke-Pearson. Obstet Gynecol 75:684, 1990



LOW MOLECULAR WEIGHT HEPARINS (LMWH)

- Enoxaparin (Lovenox), Dalteparin (Fragmin), Fondaparinux
- Effective in DVT prophylaxis
 - Equivalent to low dose heparin
 - Similar frequency of complications
- Convenience of once a day dosing
 - Dose varies between different LMWH's
- ? Cost vs. Convenience





LMWH versus LDUH in Gynecologic Surgery

(83% of patients had gynecologic cancer)

	LMWH (Dalteparin) 5000 u daily n=280	Low Dose Heparin 5000 u q 8 hours n=282
DVT in 6 wks	0	1
Pulmonary Emboli	5	1
		(p=NS)
Transfusions	39	57
		(p=NS)

Ward, Aust NZJ Obstet Gynecol 38: 91, 1998

- ### Mechanical Methods for DVT Prevention
- Graded Compression Stockings
 - TED Hose
 - Pneumatic Leg Compression
 - Sequential Compression
 - Single Chamber
 - Foot Compression



Intermittent Pneumatic Compression in Gynecologic Surgery

- Perioperative Leg Compression is effective in moderate risk patients
- Perioperative Leg Compression is **not effective** in high risk patients
- Prolonged Leg Compression is effective in high risk patients

Pneumatic Compression (5 days)	Controls
12.7%	34.6%
	(p<.005)

Clarke-Pearson, Gynecol Oncol, 18:226, 1984

WHICH IS BETTER?

Low-dose heparin
or
Intermittent Pneumatic Compression?

Low Dose Heparin vs IPC in Prevention of Postop VTE

	Low-dose Heparin (N=107)	Intermittent Pneumatic (N=101)
Compression		
Total DVT	7 (6.5%)	4 (4%)
Pulmonary Emboli	0	0
		(p = .54)

Clarke-Pearson, Am J Obstet Gynecol 168:1146, 1993

COMPLICATIONS

<p>Low-dose Heparin</p> <ul style="list-style-type: none"> • Increased postop transfusions • Increased retroperitoneal drainage • 23% with PTT > 1.5 control 	<p>Intermittent Pneumatic Calf Compression</p> <ul style="list-style-type: none"> • None
---	--

Clarke-Pearson, Am J Obstet Gynecol 168:1146, 1993

LMWH (dalteparin) vs. External Pneumatic Compression

- Prospective, Randomized Trial

	DVT	Pulmonary Emboli
External Pneumatic Compression	1/106	0
Low Molecular Weight Heparin	2/105	0

Maxwell, Obstet Gynecol 98: 989, 2001

External Pneumatic Compression vs. LMWH Complications

	External Pneumatic Compression	Low Molecular Weight Heparin
Estimated Blood Loss		
Median	350 ml	350 ml
Maximum	3100 ml	3700 ml
> 2000 ml	3	4
Transfusions (# pts)		
Intra op	22	20
Post op	12	13
Thrombocytopenia	4	2

Which is best?? Meta-analysis

Regimen	# Trials	# Patients	# DVT	Incidence (%)	Reduction of Relative Risk
Controls	54	4710	1074	25	-
Low Dose Heparin	50	7716	648	8	68
LMWH	13	4320	226	5	80
EPC	14	780	61	8	67
GC stockings	9	472	51	11	56

If Low Molecular Weight Heparins, Low Dose Heparin and External Pneumatic Compression have similar clinical benefit, how do we select the appropriate prophylactic method?

- **Cost**
- Maxwell, Obstet Gynecol 2000; 95: 206
- **Compliance**
- **Patient preference**
- Maxwell, Obstet Gynecol 2002; 100: 451

The Future: What's on the Horizon?

Combination Prophylaxis in the Extremely High-Risk

Who is at highest risk to fail External Pneumatic Compression?

1862 patients treated with EPC

Overall incidence of VTE = 1.3%

Patients with 2 or 3 of the following risk factors had a 16 fold increased risk of developing VTE

- Age > 60 years
- Cancer
- Prior VTE

Clarke-Pearson Obstet Gynecol 2003; 101: 157

The Future: What's on the Horizon?

Longer Duration of Prophylaxis

Randomized trial of patients undergoing "curative surgery" for abdominal and pelvic cancer

Treatment	%DVT (Venogram)	
	@ 1 month	@ 3 months
Enoxaparin 40mg/d x 7 d	12%	13.8%
Enoxaparin 40mg/d x 28 d	4.8%	5.5%

Bergqvist NEJM 346: 975, 2002

VTE Prophylaxis in Laparoscopic Surgery

- What is the risk?
- What prophylaxis is appropriate?

Does Laparoscopic Surgery Increase Risk of VTE ?

In Theory: Maybe (Maybe not)

- Venous Stasis
 - Intraoperative pressure 12-15 mm Hg
 - Increased femoral vein diameter
 - Increased femoral venous pressure
 - Decreased femoral venous peak outflow
 - More rapid return to normal levels of activity
 - Steep Trendelenberg position
- Endothelial injury
 - Venous distention (femoral vein) increases endothelial tears

Does Laparoscopic Surgery Increase Risk of VTE ?

In Theory: Maybe (Maybe not)

- Increased release of clotting factors
 - Decrease in plasminogen activator
 - Increase plasminogen activator inhibitor, D-dimer, Fibrinogen degradation products, soluble fibrin, prothrombin fragments 1, 2.
- Prolonged operating time vs. more rapid recovery

Laparoscopy Increases Operating Time

(Except in the hands of a gifted surgeon)

(GOG Lap-2) TAH vs LAVH, BSO, Pelvic, Paraaortic lymphadenectomy

	Median OR Time	(Range)
● Laparoscopy	3.3 hr	(0.7-10.1 hr)
● Laparotomy	2.2 hr	(0.7-6.3 hr)

What is the Incidence of VTE Following Laparoscopic Surgery?

- Only randomized prospective trial is GOG Lap-2.
- Endpoint: **Clinical** diagnosis of VTE
- Potential for bias
 - not blinded
 - no objective/prospective endpoint
- No record of which prophylactic method used (if any); not randomized

GOG Lap-2 Trial

Laparoscopic vs. Laparotomy Hysterectomy, BSO, pelvic and paraaortic lymphadenectomy (endometrial cancer)

Complication	Laparoscopy (n=1682)	Laparotomy (n=900)
DVT	0.8%	1.3%
Pulmonary Embolism	1.2%	1.3%
Death in 6 weeks	0.5%	0.7%
9 Deaths from PE		

Should We Provide VTE Prophylaxis for Laparoscopic Surgery?

Summary:

What should we do to prevent VTE following gynecologic surgery?

VTE Prophylaxis Guidelines ACCP Consensus 2004

- Low Risk: early mobilization
 - Brief procedure < 30 min. Benign Disease (1C)
- Laparoscopy with additional risk factors (1C)
 - LDUH, LMWH, IPC, GCS
- Prophylaxis for ALL major gyn surgery
 - Benign disease without additional risk factors
 - LDUH 5000u q 12 h
 - LMWH < 3400 u q day
 - IPC (1B)

Geerts W, et al. Chest 2004; 126: 338S

VTE Prophylaxis Guidelines ACCP Consensus 2004

- Major Gyn Surgery Patients with additional risk factors
 - LDUH 5000 u tid
 - LMWH > 3400 u daily
 - IPC (1A)
 - Combination (1C)
 - Prophylaxis should continue until hospital discharge
- Continued prophylaxis: Cancer and > 60 years or prior VTE
 - Continue for 2-4 weeks (2C)

Geerts W, et al. Chest 2004; 126: 338S

Prevention of Postoperative VTE Issues

- Degree of risk for individual patient
- Outcomes Research: What are our best options?
- Intensity of prophylaxis:
- Management Recommendations/Consensus Statements
- Future directions
 - Combination prophylaxis
 - Prolonged prophylaxis
 - laparoscopic surgery

Thank You